Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...

Sanofi and Regeneron's checkpoint inhibitor Libtayo has tripled its approved uses in Europe, after getting the nod for the treatment of advanced basal cell carcinoma (BCC) and advanced non-small ...

Along with first-line PDL1-positive NSCLC, Libtayo is also used to treat two forms of skin cancer – cutaneous squamous cell carcinoma and basal cell carcinoma. Merck claims adjuvant win in ...

THIO sequenced with Libtayo extended overall survival in those with non–small cell lung cancer who progressed on two or more ...

Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase ...

UCR scientists have developed new light-sensitive chemicals that can radically improve the treatment of aggressive cancers ...

More than one-quarter of blood or marrow transplant survivors developed cutaneous malignant neoplasms, according to study results.Researchers identified several risk factors, including older age, ...

in combination with Regeneron's immunotherapy drug Libtayo in patients with advanced non-small cell lung cancer (NSCLC) in its ongoing Phase 2a study. IMM-1-104 is currently in a Phase 1/2a study ...

Feb. 7, 2025 — Pancreatic cancer patients may benefit from future precision treatments as a new study shows how some tumors may potentially be more susceptible to ... Personalized Cancer ...

but its importance goes beyond this single trial as the outcome should have read-through to other combination trials of Libtayo and fianlimab in melanoma patients, and potentially lung cancer and ...